Stefan Grotegut
Executive Director, High-Throughput Screening, Eli Lilly and Company
Stefan Grotegut is listed as Executive Director, High-Throughput Screening, Eli Lilly and Company. Stefan is scheduled to speak at SLAS 2027 International Conference & Exhibition on 30 January 2027.
Compiled from published conference agendas; not yet confirmed by Stefan. Is this you? Claim this profile.
About
Stefan Grotegut, PhD has a strong background in oncology and 17 years of experience in the academic, government, and pharmaceutical company drug discovery processes. He is co-author of several highimpact publications and a recipient of multiple prestigious awards. Dr. Grotegut received his PhD from the University of Basel, Switzerland in 2006 focusing on signaling pathways that lead to the epithelial-mesenchymal-transition (EMT) of cancer cells and ultimately cause metastasis. He discovered the essential involvement of transcription factors like Snail in response to growth factor stimulation as a key factor in the transition from benign to malignant tumor cells. He then pursued a postdoctoral fellowship at the Sidney Kimmel Cancer Denter and later Sanford Burnham Prebys Medical Discovery Institute investigating the roles of SCF E3 ligases (in particular F-box proteins) in tumorigenesis and tumor progression. To apply his knowledge to the drug discovery process, he joined the Conrad Pre
Upcoming
SLAS 2027 International Conference & Exhibition 30 January 2027 – 3 February 2027
- Assay Guidance Workshop for High-Throughput Screening and Lead Discovery Speaker · 30 January 2027
Spoke alongside
People who have shared a session with Stefan at events on B2DB.
- Benjamin Bader Director / Head of Screening · Nuvisan 1 shared session
- Jayme Dahlin Medical Director, Clinical Development · Oruka Therapeutics 1 shared session
- Joe Trask Life Sciences Segment Manager, NA · Revvity 1 shared session
- Michelle Arkin Professor, Pharm Chem; co-Director, Small Molecule Discovery Center · University of California - San Francisco 1 shared session
- Nathan Coussens Scientific Director, Molecular Pharmacology Laboratory · Frederick National Laboratory for Cancer Research 1 shared session
- Sarine Markossian Editor-in-Chief, Assay Guidance Manual (AGM) and Lead, AGM Translational Science Resources Program · NCATS/NIH 1 shared session
- Terry Riss Scientific Ambassador · Promega Corporation 1 shared session
- Thomas D.Y. Chung Director, Translational Programs Outreach · Sanford Burnham Prebys Medical Discovery Institute 1 shared session